Earnings ·
Whitehawk Therapeutics reported a net loss of $16.6 million for the quarter ended June 30, 2026, compared to a $52.6…
WHWKWhitehawk Therapeutics, Inc.
Whitehawk Therapeutics reported a net loss of $16.6 million for the quarter ended June 30, 2026, compared to a $52.6 million loss in the prior year period. Research and development expenses decreased to $12.9 million from $48.8 million, primarily due to the absence of a $38.0 million upfront license fee paid to WuXi Biologics in 2025. The company ended the quarter with $190.0 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into the second half of 2028 following an $87.5 million private placement equity financing announced in May 2026. Clinically, patient enrollment continues for Phase 1 trials of HWK-007 and HWK-016, while a Phase 1 trial for HWK-206 is scheduled to initiate in Q3 2026. The company also entered into an option agreement with Hangzhou DAC for CPT113 access and a collaboration with Biocytogen for bispecific antibody ADC development. Whitehawk Therapeutics operates as a clinical-stage oncology therapeutics company focused on developing antibody drug conjugate cancer treatments.